Text Size
1570 studies found for:    docetaxel

Modify this search | How to Use Search Results

Show Display Options
Rank Status Study
1 Completed Study of Usefulness of Genotyping to Predict Docetaxel Exposure and Adverse Events
Conditions: CYP3A Phenotyping;   CYP3A5 and MDR1 Genotyping;   Docetaxel Toxicity;   Associations Between Genetic Data and Docetaxel Toxicity
Intervention: Drug: docetaxel + CEF
2 Unknown † Biomarker Study for Sunitinib and Docetaxel in Prostate Cancer
Condition: Hormone Refractory Prostate Cancer
Interventions: Drug: Docetaxel * Sunitinib;   Drug: Docetaxel
3 Completed Study Comparing Concomitant Docetaxel + Gemcitabine to Sequential Therapy of Docetaxel Followed by Gemcitabine
Condition: Breast Cancer
Interventions: Drug: Docetaxel;   Drug: Gemcitabine, Docetaxel
4 Completed Pharmacokinetic Study of CKD-810 and Taxotere to Treat Patient With Advanced Solid Cancer
Condition: Advanced Solid Cancers
Intervention: Drug: CKD-810, Taxotere inj.
5 Terminated Study to Evaluate Combination Treatment of MGCD0103 and Docetaxel (Taxotere®) for Subjects With Advanced Cancer Tumors
Conditions: Breast Cancer;   Lung Cancer;   Pulmonary Cancer;   Non-Small-Cell Lung Carcinoma;   Prostate Cancer;   Prostatic Cancer;   Gastric Cancer;   Stomach Cancer
Intervention: Drug: MGCD0103 & Docetaxel
6 Completed Docetaxel and Trastuzumab With or Without Carboplatin in Treating Women With HER2-Positive Breast Cancer
Condition: Breast Cancer
Interventions: Biological: trastuzumab;   Drug: carboplatin;   Drug: docetaxel;   Biological: trastuxumab;   Drug: Docetaxel
7 Completed
Has Results 		A Study of Docetaxel Monotherapy or DOXIL and Docetaxel in Patients With Advanced Breast Cancer
Condition: Breast Cancer
Interventions: Drug: Docetaxel;   Drug: DOXIL
8 Not yet recruiting Study of SPI-1620 in Combination With Docetaxel Versus Docetaxel Alone for Patients With Non Small-cell Lung Cancer (NSCLC)
Condition: Non Small Cell Lung Cancer (NSCLC)
Interventions: Drug: SPI-1620 & Docetaxel;   Drug: Docetaxel
9 Active, not recruiting Randomized Study of Docetaxel +/- ZD6474 in Metastatic TCC
Conditions: Transitional Cell Carcinoma;   Urothelial Cancer
Interventions: Drug: Docetaxel;   Drug: Zactima;   Drug: Placebo
10 Withdrawn Docetaxel/Carboplatin Versus Docetaxel/Caelyx in Pretreated Patients With Ovarian Carcinoma
Condition: Ovarian Cancer
Interventions: Drug: Docetaxel;   Drug: Carboplatin;   Drug: Liposomal doxorubicin
11 Unknown † Docetaxel Versus Docetaxel Plus Cisplatin Versus Docetaxel Plus S-1 as Second-line Chemotherapy in Metastatic Gastric Cancer
Condition: Gastric Cancer
Interventions: Drug: docetaxel;   Drug: docetaxel, cisplatin;   Drug: docetaxel, S-1
12 Completed A Study Comparing AT-101 in Combination With Docetaxel and Prednisone Versus Docetaxel and Prednisone in Men With Chemotherapy-Naïve Metastatic Hormone Refractory Prostate Cancer (HRPC)
Condition: Hormone Refractory Prostate Cancer
Interventions: Drug: AT-101, prednisone and docetaxel;   Drug: placebo, prednisone and docetaxel
13 Completed Docetaxel (Taxotere), Vinorelbine, and Bevacizumab, as Adjuvant Chemotherapy for Patients With Resected Stage I-III Non-small Cell Lung Cancer
Condition: Lung Cancer
Intervention: Drug: Bevacizumab (Avastin), Taxotere (Docetaxel), Vinorelbine Tartrate (Navelbine)
14 Completed Cisplatin and Docetaxel Plus Docetaxel and Radiotherapy With Amifostine for Squamous Cell Carcinoma of the Head and Neck
Conditions: Cancer of Head and Neck;   Head Cancer;   Head and Neck Cancer;   Neck Cancer;   Neck Neoplasms
Interventions: Drug: Cisplatin;   Drug: Docetaxel;   Procedure: Radiotherapy;   Drug: Amifostine
15 Completed The Effects Of GW679769 (Casopitant) On The Pharmacokinetics Of Docetaxel In Subjects With Cancer
Conditions: Nausea and Vomiting, Chemotherapy-Induced;   Cancer
Interventions: Drug: Docetaxel;   Drug: Casopitant/Docetaxel
16 Recruiting A Phase 1b Dose Escalation Trial of PSK®/Placebo With Docetaxel to Treat Metastatic Castration-resistant Prostate Cancer
Condition: Prostatic Neoplasms
Interventions: Drug: Docetaxel, PSK®;   Drug: Docetaxel, Placebo
17 Recruiting Phase 2 Study of EC145 Alone Versus EC145+Docetaxel Versus Docetaxel Alone in Participants With FR(++) 2nd Line Non Small Cell Lung Cancer
Condition: Non Small Cell Lung Cancer
Interventions: Drug: EC145;   Drug: EC145 + Docetaxel;   Drug: Docetaxel;   Drug: EC20
18 Completed Phase III Randomized, Placebo Controlled, Trial Of Docetaxel Versus Docetaxel Plus ZD1839 (Iressa, Gefitinib, NSC 715055) In Performance Status 2 Or Previously Treated Patients With Recurrent Or Metastatic Head And Neck Cancer
Conditions: Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma;   Recurrent Metastatic Squamous Neck Cancer With Occult Primary;   Recurrent Salivary Gland Cancer;   Recurrent Squamous Cell Carcinoma of the Hypopharynx;   Recurrent Squamous Cell Carcinoma of the Larynx;   Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity;   Recurrent Squamous Cell Carcinoma of the Nasopharynx;   Recurrent Squamous Cell Carcinoma of the Oropharynx;   Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity;   Recurrent Verrucous Carcinoma of the Larynx;   Recurrent Verrucous Carcinoma of the Oral Cavity;   Salivary Gland Squamous Cell Carcinoma;   Stage IV Squamous Cell Carcinoma of the Hypopharynx;   Stage IV Squamous Cell Carcinoma of the Nasopharynx;   Stage IVA Salivary Gland Cancer;   Stage IVA Squamous Cell Carcinoma of the Lip and Oral Cavity;   Stage IVA Squamous Cell Carcinoma of the Oropharynx;   Stage IVA Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity;   Stage IVA Verrucous Carcinoma of the Larynx;   Stage IVA Verrucous Carcinoma of the Oral Cavity;   Stage IVB Salivary Gland Cancer;   Stage IVB Squamous Cell Carcinoma of the Larynx;   Stage IVB Squamous Cell Carcinoma of the Lip and Oral Cavity;   Stage IVB Squamous Cell Carcinoma of the Oropharynx;   Stage IVB Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity;   Stage IVB Verrucous Carcinoma of the Larynx;   Stage IVB Verrucous Carcinoma of the Oral Cavity;   Stage IVC Salivary Gland Cancer;   Stage IVC Squamous Cell Carcinoma of the Larynx;   Stage IVC Squamous Cell Carcinoma of the Lip and Oral Cavity;   Stage IVC Squamous Cell Carcinoma of the Oropharynx;   Stage IVC Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity;   Stage IVC Verrucous Carcinoma of the Larynx;   Stage IVC Verrucous Carcinoma of the Oral Cavity;   Tongue Cancer;   Untreated Metastatic Squamous Neck Cancer With Occult Primary
Interventions: Drug: docetaxel;   Other: placebo;   Drug: gefitinib;   Other: laboratory biomarker analysis;   Other: pharmacological study
19 Terminated
Has Results 		Randomized, Multi-center, Open-label, Study of PR104 Versus PR104/Docetaxel in Non-Small Cell Lung Cancer (NSCLC)
Condition: Non-Small Cell Lung Cancer
Interventions: Drug: PR104;   Drug: docetaxel;   Drug: Granulocyte colony-stimulating factor
20 Completed Phase 1/2 Study of Vascular Disrupting Agent NPI-2358 + Docetaxel in Patients With Advanced Non-Small Cell Lung Cancer
Condition: Cancer
Interventions: Drug: docetaxel;   Drug: NPI-2358 + docetaxel
To Top

Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results
† Indicates status has not been verified in more than two years